Variable transcriptional adaptation between the laboratory (H37Rv) and clinical strains (S7 and S10) of Mycobacterium tuberculosis under hypoxia

Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases
Santhi Devasundaram, Alamelu Raja

Abstract

Tuberculosis continues to be a major public health problem in many parts of the world, despite intensified efforts taken to control the disease. The remarkable success of M. tuberculosis as a pathogen is largely due to its ability to persist within the host for long periods. To develop the effective intervention strategies, understanding the biology of persistence is highly required. Accumulating evidences showed oxygen deprivation (hypoxia) as a potential stimulus for triggering the transition of M. tuberculosis to a non-replicating persistent state analogous to latency in vivo. To date, in vitro hypoxia experimental models used the laboratory adapted isolate H37Rv and very little is known about the behavior of clinical isolates that are involved during disease outbreaks. Hence, we compared the transcription profiles of H37Rv and two south Indian clinical isolates (S7 and S10) under hypoxia to find differences in gene expression pattern. The main objective of this current work is to find "differentially regulated genes" (genes that are down regulated in H37Rv but upregulated in both the clinical isolates) under hypoxia. Microarray results showed, a total of 502 genes were down regulated in H37Rv under hypoxia and 10 out of 502...Continue Reading

References

Dec 1, 1995·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·S DasP R Narayanan
Aug 18, 2000·Immunology and Cell Biology·J A Triccas, B Gicquel
Mar 14, 2002·Proceedings of the National Academy of Sciences of the United States of America·R BroschS T Cole
Oct 24, 2003·Infection and Immunity·Rakesh Kumar ChoudharySeyed E Hasnain
Nov 19, 2003·Proceedings of the National Academy of Sciences of the United States of America·Juliano TimmJohn D McKinney
Apr 9, 2004·Proceedings of the National Academy of Sciences of the United States of America·Adel M TalaatStephen Albert Johnston
Jun 23, 2004·Tuberculosis·D G Niranjala MuttucumaruTanya Parish
Nov 13, 2004·Trends in Microbiology·Sharon L KendallNeil G Stoker
Dec 21, 2004·Nature Reviews. Microbiology·Helena I M Boshoff, Clifton E Barry
May 24, 2005·Infection and Immunity·Eugenie DubnauIssar Smith
Jul 8, 2005·Journal of Clinical Microbiology·Anthony G TsolakiPeter M Small
Aug 23, 2006·Infection and Immunity·N BanaieeJ D Ernst
Dec 5, 2006·Trends in Microbiology·Peter Andersen
Nov 20, 2008·Journal of Medical Microbiology·Su-Young KimJeong-Kyu Park
Apr 25, 2009·Cellular Microbiology·Tige R RustadDavid R Sherman
Oct 17, 2009·Journal of Theoretical Biology·Sandeep K Kushwaha, Madhvi Shakya
Feb 15, 2011·Clinical & Developmental Immunology·Samantha L Sampson
Jul 8, 2011·Frontiers in Microbiology·Martin I VoskuilGary K Schoolnik
Oct 26, 2011·The Journal of Infectious Diseases·Victoria O KasprowiczAjit Lalvani
Oct 3, 2012·PLoS Computational Biology·Xin FangJaques Reifman
Oct 17, 2013·Frontiers in Immunology·Shajo Kunnath-Velayudhan, Steven Anthony Porcelli
Dec 24, 2013·Mediterranean Journal of Hematology and Infectious Diseases·Lanfranco FattoriniFederico Giannoni
Dec 17, 2014·Organic & Biomolecular Chemistry·Gang LiuJie Wu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.

© 2022 Meta ULC. All rights reserved